OBJECTIVES Lutetium-177 can be made with high specific activity and with no other isotopes of lutetium present, referred to as "No Carrier Added" (NCA) 177Lu. We have radiolabelled DOTA-conjugated peptide DOTA-(Tyr3)-octreotate with NCA 177Lu ("NCA-LuTATE") and used it in nearly 40 therapeutic administrations for subjects with neuroendocrine tumours or meningiomas. In this paper, we report on o...

Objective(s):Lutetium-177 can be made with high specific activity and with no other isotopes of lutetium present, referred to as “No Carrier Added” (NCA) 177Lu. We have radiolabelled DOTA-conjugated peptide DOTA‐(Tyr3)‐octreotate with NCA 177Lu (“NCA-LuTATE”) and used it in nearly 40 therapeutic administrations for subjects with neuroendocrine tumours or meningiomas. In this paper, we report on...

objective(s):lutetium-177 can be made with high specific activity and with no other isotopes of lutetium present, referred to as “no carrier added” (nca) 177lu. we have radiolabelled dota-conjugated peptide dota‐(tyr3)‐octreotate with nca 177lu (“nca-lutate”) and used it in nearly 40 therapeutic administrations for subjects with neuroendocrine tumours or meningiomas. in this paper, we report on...

Objective(s): To investigate and compare quantitative accuracy of kidney absorbed dose measures made from both 2D and 3D imaging in patients receiving 177LuDOTATATE (Lutate) for treatment of neuroendocrine tumours (NETs). Methods: Patients receiving Lutate therapy underwent both whole body planar imaging and SPECT/CT imaging over the kidneys at time points 0.5, 4, 24, and 96-120 hours after inj...

The paper by Denoyer et al. in the current issue of The Journal of Nuclear Medicine (1) explores the possibility of quantifying radiation-induced DNA damage after internal treatment with 177Lu-DOTA-octreotate (LuTate) peptide receptor radionuclide therapy for metastatic or inoperable neuroendocrine tumors. Radiation-induced DNA damage was quantified by analyzing the kinetics of phosphorylated h...

Imaging of neuroendocrine tumours (NET) poses significant challenges because of the heterogeneous biology of the tumours that are represented by this class of neoplasia. NET can range from benign lesions to highly aggressive cancers. Structural imaging techniques have suboptimal sensitivity in most published series and diagnosis is often delayed until metastatic disease is present. Current guid...